OakChart

Helus Pharma Inc

HELPHealthcare·Biotechnology·Canada·Small·NASD·Nov 11 • 11:15 AM ET

9.70+0.63 (6.95%)
2026-11-11 17:15 CET
Market cap
662.66 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-171.20 USD m
Free cash flow, TTM
-143.27 USD m
EPS diluted, TTM
-4.25
P/E
-
Compare

Price

HELP against its 20, 50 and 200-day averages
2050200miss
5.0010.0015.003.6M7.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26HELPclose 9.7020-day 9.9950-day 11.36200-day 7.779.7052w high52w low

36.0% under the 52-week high of 15.15 on 18 Sep 2026. 52-week low 3.76 on 9 Jun 2026. Last 15 sessions, 39.5% high to low

Profile

HELP
52-week range, 52% of the way up
3.7615.15

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Employees100
IPOSep 13, 2019
Beta0.64
ATR, 14d0.87
Rel volume0.72
Short float5.11%
Insider own28.57%
Inst own36.78%

Snapshot

6 groups

Valuation

Index-
Market Cap708.68M
Enterprise Value542.31M
Income-171.20M
Sales0.00M
Book/sh3.91
Cash/sh2.28
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees100
IPOSep 13, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.48
P/C4.26
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio10.97
Current Ratio10.97
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.25
EPS next Y-2.11
EPS next Q-0.70
EPS this Y37.20%
EPS next Y20.76%
EPS next 5Y27.67%
EPS past 3/5Y16.70% 14.41%
Sales past 3/5Y- -
EPS Y/Y TTM7.55%
Sales Y/Y TTM-
EPS Q/Q16.81%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.-7.00% -

Ownership

Insider Own28.57%
Insider Trans3.92%
Inst Own36.78%
Inst Trans12.01%
ROA-72.78%
ROE-86.94%
ROIC-70.72%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-2.90%
SMA50-14.63%
SMA20024.82%
Trades-

Technical

Shs Outstand61.98M
Shs Float52.18M
Short Float5.11%
Short Ratio1.65
Short Interest2.66M
52W High15.15 -35.97%
52W Low3.76 157.98%
Volatility7.78% 9.05%
ATR (14)0.87
RSI (14)45.86
Beta0.64
Rel Volume0.72
Avg Volume1.61M
Volume355,898

Performance

Perf Week11.75%
Perf Month-7.62%
Perf Quarter-15.28%
Perf Half Y87.26%
Perf YTD18.58%
Perf Year52.76%
Perf 3Y-40.36%
Perf 5Y-86.42%
Perf 10Y-
Recom1.11
Target Price43.75
Prev Close9.07
Price9.70
Change %6.95%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Jul 27, 2026InitiatedWWells FargoOverweight$16+64.9%
Apr 13, 2026InitiatedTTD CowenBuy$8-17.5%
Feb 02, 2026InitiatedJJefferiesBuy$22+126.8%
Mar 13, 2025InitiatedGGuggenheimBuy$35+260.8%
Nov 19, 2021DowngradeMMaxim GroupBuy → Hold

Peers

Mkt cap
TickerCompanyMkt cap
GHRSGH Research PLC1.34B
DFTXDefinium Therapeutics Inc4.72B
CMPSCompass Pathways Plc ADR1.32B
ANROAlto Neuroscience Inc1.17B
SPTXSeaport Therapeutics Inc1.13B
PBMPsyence Biomedical Ltd12.25M
DRUGBright Minds Biosciences Inc216.17M
AXSMAxsome Therapeutics Inc7.82B
NMRANeumora Therapeutics Inc86.35M
ENVBEnveric Biosciences Inc6.83M

Insider trading

9 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Cavers GregChief Financial OfficerSep 29 '26Buy12.913,00038,7303,000Oct 01 08:13 PM
Halstead MichaelChief Executive OfficerSep 21 '26Buy13.47100,0001,347,050168,568Sep 21 05:07 PM
Glavine PaulChief Growth OfficerSep 08 '26Buy12.47100,0001,247,1904,271,252Sep 11 09:04 AM
Glavine PaulChief Growth OfficerSep 08 '26Buy12.47100,0001,247,1904,271,252Sep 11 09:03 AM
So Eric H. L.Executive ChairSep 08 '26Buy12.39100,0001,238,6704,465,014Sep 11 09:01 AM
So Eric H. L.Executive ChairSep 04 '26Buy12.09100,0001,208,9004,365,014Sep 10 06:21 AM
Glavine PaulChief Growth OfficerSep 03 '26Buy11.78100,0001,178,2804,171,252Sep 10 06:19 AM
So Eric H. L.Executive ChairSep 01 '26Buy11.8095,0001,121,4754,265,014Sep 09 05:47 PM
Glavine PaulChief Growth OfficerAug 31 '26Buy11.5990,0001,042,6774,071,252Sep 09 11:03 AM

Held by

AUM
TickerCompanyAUM
PSILAdvisorShares Psychedelics ETFAUM: 43.26M
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.35B
GWXState Street SPDR S&P International Small Cap ETFAUM: 906.57M
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M
TNXTT. Rowe Price Innovation Leaders ETFAUM: 18.62M

News

latest 14 of 206
  • Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference (GlobeNewswire)
  • Helus Pharma Announces Co-Founders' Transition from Executive Leadership as Company Advances Toward Next Stage of Development (GlobeNewswire)
  • Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
  • Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026 (GlobeNewswire)
  • Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors (GlobeNewswire) +6.45%
  • Loading…
  • Helus Pharma to Host Investor Presentation on October 21, 2026 (GlobeNewswire)
  • Helus Pharma Announces Completion of Legal Name Change (GlobeNewswire)
  • Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change (GlobeNewswire) -5.03%
  • Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit (GlobeNewswire) +10.43%
  • Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026 (GlobeNewswire)
  • Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York (GlobeNewswire) -6.14%
  • Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York (GlobeNewswire) +10.41%
  • Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q12026-08-14-0.910-0.851-0.9100.000.008
2025Q42026-06-30-0.916-0.834-0.9350.000.008
2025Q32026-02-16-1.000-0.760-1.0040.000.007
2025Q22025-11-13-1.353-1.050-1.3930.000.005
2025Q12025-08-13-1.023-0.956-1.0990.000.005
2024Q42025-07-01-1.027-0.871-1.0200.000.006
2024Q32025-02-11-0.481-0.744-0.3770.000.004
2024Q22024-11-13-2.023-0.026-2.0960.000.004
2024Q12024-08-08-0.022-0.032-0.5530.000.003
2023Q42024-06-25-1.292-1.121-0.7910.000.006
2023Q32024-02-14-2.523-1.197-2.5360.000.004
2023Q22023-11-15-1.406-1.372-1.4370.000.004
2023Q12023-08-14-1.782-1.668-1.9910.000.006
2022Q42023-06-27-2.006-1.680-1.9650.000.006
2022Q32023-02-14-1.706-1.980-1.5920.000.006
2022Q22023-01-31-1.695--1.6050.00-5

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-8.903-7.224-9.2570.580.47
2021FY-11.746-11.693-12.2520.000.00
2022FY-7.334-7.030-7.3570.000.00
2023FY-0.183-0.169-2.8940.000.00
2024FY-4.094-3.523-4.0980.000.00
2025FY-4.250-4.060-4.2500.000.00
2026FY--2.669--0.00
2027FY--2.115--10.10
2028FY--1.608--145.98
2029FY--0.270--441.42
2030FY-2.184--766.46

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q2S2026-08-147000.000.000.00
2026Q2S2026-07-166000.000.000.00
2026Q2S2026-07-155000.000.000.00
2026Q2S2026-07-084000.000.000.00
2026Q2S2026-06-303000.000.000.00
2026Q2S2026-04-106000.000.000.00
2026Q2S2026-03-055000.000.000.00
2026Q2S2026-02-214000.000.000.00
2026Q2S2026-02-165000.000.000.00
2026Q2S2025-12-025000.000.000.00
2026Q2S2025-11-194000.000.000.00
2026Q2S2025-11-133000.000.000.00
2026Q2S2025-11-112000.000.000.00
2026Q2S2025-11-102000.000.000.00

Estimate history

EPS, annual-0.267-0.542-0.208-9.257-12.252-7.357-2.894-4.022-4.253-4.2452
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.553-2.096-0.377-1.02-1.099-1.393-1.004-0.935-0.914
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Sales, annual0000.653000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Shares, annual0.3610.3610.3744.1444.6085.2820.00121.61151.63261.984
Period201720182019202020212022202320242025MRQ
Shares, quarterly19.58520.00120.00121.61123.03326.10149.89451.63261.984
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.650.000.00
Cost of Goods Sold Incl. D&A0.110.120.340.310.190.130.500.000.00
Gross Profit-0.11-0.12-0.34-0.31-0.19-0.130.150.000.00
Selling, General and Administrative Excl. Other166.93142.47102.5758.1338.7550.7823.230.080.06
Research and Development102.3586.5939.4823.9919.2714.032.50--
Other Operating Expense0.000.000.000.000.000.000.390.000.00
Operating Income-167.04-142.59-102.91-58.45-38.94-50.91-23.47-0.08-0.06
Interest Expense-2.920.00-0.000.000.000.000.00
Unusual Expense5.505.500.000.000.452.720.220.070.02
Net Income Before Taxes-171.20-148.00-81.34-57.89-35.90-53.94-24.36-0.14-0.08
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-171.20-148.00-81.34-57.89-35.90-53.94-24.36-0.14-0.08
Net Income From Continuing Operations-171.20-148.00-81.34-57.89-35.90-53.94-24.36-0.14-0.08
Net Income-171.20-148.00-81.34-57.89-35.90-53.94-24.36-0.14-0.08
EPS (Recurring)-3.20-4.14-4.02-2.89-7.29-11.82-9.20-0.01-0.18
EPS (Basic, Before Extraordinaries)-4.25-4.25-4.02-2.89-7.36-12.25-9.26-0.01-0.21
EPS (Diluted)-4.25-4.25-4.02-2.89-7.36-12.25-9.26-0.01-0.21
EBITDA-166.93-142.47-102.57-58.13-38.75-50.78-23.43-0.08-0.06
Non-Operating Income (Expense)1.343.0121.580.563.49-0.31-0.670.010.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense21.6810.8630.8210.293.5414.388.74-0.00
Price To Sales Ratio------16.44--
Gross Margin------23.15--
Operating Margin-------3,592.01--
Net Margin-------3,729.16--
Shares Outstanding61.9851.6321.6120.005.284.614.1414.200.37
Market Capitalization662.66662.66133.37170.0477.2472.63164.24281.18281.18

Income statement, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.030.020.030.040.040.090.10
Gross Profit-0.03-0.03-0.02-0.03-0.04-0.04-0.09-0.10
Selling, General and Administrative Excl. Other49.0547.8341.1928.8724.5923.1522.2942.60
Research and Development30.7628.8923.8618.8515.0013.2213.436.68
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-49.08-47.86-41.21-28.89-24.62-23.19-22.38-42.71
Interest Expense0.000.000.00-2.920.00--
Unusual Expense0.000.000.365.140.000.000.000.00
Net Income Before Taxes-47.82-47.00-42.67-33.72-24.61-21.31-7.54-41.93
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-47.82-47.00-42.67-33.72-24.61-21.31-7.54-41.93
Net Income From Continuing Operations-47.82-47.00-42.67-33.72-24.61-21.31-7.54-41.93
Net Income-47.82-47.00-42.67-33.72-24.61-21.31-7.54-41.93
EPS (Recurring)-0.91-0.93-1.00-1.24-1.10-1.02-0.38-2.10
EPS (Basic, Before Extraordinaries)-0.91-0.93-1.00-1.39-1.10-1.02-0.38-2.10
EPS (Diluted)-0.91-0.93-1.00-1.39-1.10-1.02-0.38-2.10
EBITDA-49.05-47.83-41.19-28.86-24.59-23.15-22.29-42.60
Non-Operating Income (Expense)1.260.86-1.100.312.931.8814.850.78
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.575.264.480.380.751.462.3924.53
Shares Outstanding61.9851.6349.8926.1023.0321.6120.0020.00
Market Capitalization662.66240.17408.13139.00176.49133.37176.41177.81

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019FY2018FY
Cash & Short Term Investments157.2693.81154.4412.2942.9550.940.170.240.33
Short Term Receivables5.034.093.312.251.681.060.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets22.2417.423.752.592.090.900.000.000.00
Total Current Assets184.52115.32161.4917.1346.7252.900.180.240.34
Net Property, Plant & Equipment0.200.100.400.330.390.440.000.000.00
Total Investments and Advances0.000.000.000.000.190.000.000.000.00
Intangible Assets66.4564.2761.2922.3620.0019.950.000.000.00
Other Assets0.000.000.000.000.000.000.000.070.02
Total Assets251.17179.69223.1839.8267.3073.290.180.310.35
Short Term Debt Incl. Current Port. of LT Debt0.000.000.220.000.000.000.000.000.00
Accounts Payable0.000.000.000.004.212.220.000.000.00
Other Current Liabilities19.3814.887.254.182.121.680.020.010.01
Total Current Liabilities19.3814.887.464.186.333.900.020.010.01
Long Term Debt0.000.000.000.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.870.000.000.00
Total Liabilities19.3814.887.464.186.334.770.020.010.01
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity231.79164.81215.7235.6460.9768.520.150.300.34
Total Shareholders Equity231.79164.81215.7235.6460.9768.520.150.300.34
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity231.79164.81215.7235.6460.9768.520.150.300.34
Total Liabilities & Stockholders Equity251.17179.69223.1839.8267.3073.290.180.310.35
Book Value Per Share4.497.6310.796.7513.2316.540.010.800.94
Tangible Book Value Per Share3.204.657.722.528.8911.720.010.800.94
Full-Time Employees10050-------
Price to Book Ratio2.320.761.852.171.752.401,831.741,147.89-
Return on Assets-68.70-40.38-44.02-67.02-76.73-66.21-57.71-22.97-49.24
Return on Equity-74.63-42.75-46.06-74.32-83.31-70.81-61.91-23.79-60.64
Return on Invested Capital-63.85-49.35-26.83-100.73-88.46-35.56-91.60-25.27-51.31
Quick Ratio9.527.7521.654.097.3813.577.7823.3227.38
Current Ratio9.527.7521.654.097.3813.577.7823.3227.38

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019FY
Net Income-172.32-148.00-81.34-57.89-35.90-53.94-24.36-0.14-0.08
Depreciation0.110.120.340.310.190.130.04--
Other Funds (Non Cash)28.7815.8615.2110.211.1917.5810.900.070.02
Funds from Operations-143.44-132.01-65.79-47.36-34.77-36.22-13.43-0.07-0.06
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.63-1.26-7.04-3.73-1.090.17-0.960.01-0.00
Cash from Operating Activities-141.80-133.27-72.83-51.09-35.85-36.05-14.39-0.06-0.06
Capital Expenditures-1.47-1.37-1.41-0.53-2.50-0.41-0.170.00-0.03
Net Assets From Acquisitions0.000.000.005.660.000.00-0.720.000.00
Sale of Fixed Assets and Businesses0.000.010.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.00-0.200.000.000.00
Purchase of Investments0.000.000.000.000.00-0.200.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-1.47-1.36-1.415.13-2.50-0.61-0.900.00-0.03
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock211.61173.8914.73188.8010.2528.5362.560.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock211.61173.8914.73188.8010.2528.5362.560.000.00
Proceedsfrom Stock Options183.24145.7414.73188.769.9825.1357.650.000.00
Issuance or Reduction of Debt, Net-19.9724.350.000.000.000.000.000.000.00
Change in Long Term Debt-19.9724.350.000.000.000.000.000.000.00
Issuance of Long Term Debt0.3444.500.000.000.000.000.000.000.00
Reduction of Long Term Debt-20.30-20.150.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities191.64198.2414.52188.6910.2528.5362.560.000.00
Exchange Rate Effect-0.21-0.276.54-0.120.13-0.15-0.02--
Net Change in Cash48.1563.34-53.18142.61-27.98-8.2847.25-0.06-0.09
Free Cash Flow-143.27-134.64-74.24-51.10-35.96-36.14-14.49-0.06-0.06
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Cash & Short Term Investments166.37157.26195.1383.75118.6993.81
Short Term Receivables5.045.034.774.744.114.09
Inventories0.000.000.000.000.000.00
Other Current Assets21.2922.2423.0026.0920.8517.42
Total Current Assets192.69184.52222.90114.58143.65115.32
Net Property, Plant & Equipment0.180.200.190.120.080.10
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets66.7866.4567.0366.5467.0864.27
Other Assets0.000.000.000.000.000.00
Total Assets259.65251.17290.11181.25210.81179.69
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities17.5719.3816.1813.3614.5514.88
Total Current Liabilities17.5719.3816.1813.3614.5514.88
Long Term Debt0.000.000.0028.8944.500.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities17.5719.3816.1842.2559.0514.88
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity242.09231.79273.93139.00151.76164.81
Total Shareholders Equity242.09231.79273.93139.00151.76164.81
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity242.09231.79273.93139.00151.76164.81
Total Liabilities & Stockholders Equity259.65251.17290.11181.25210.81179.69
Book Value Per Share3.914.495.495.336.597.63
Tangible Book Value Per Share2.833.204.152.783.684.65
Full-Time Employees-100---50
Price to Book Ratio2.320.871.540.891.100.76
Return on Assets-72.78-68.70-52.45-46.44-45.55-40.52
Return on Equity-86.94-74.63-55.47-53.20-53.55-42.90
Return on Invested Capital-19.75-20.27-15.58-20.09-12.54-12.93
Quick Ratio10.979.5213.788.589.877.75
Current Ratio10.979.5213.788.589.877.75

Cash flow, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Net Income-47.82-48.76-41.86-33.89-24.61-19.81
Depreciation0.030.030.020.030.040.04
Other Funds (Non Cash)11.596.154.746.28-1.200.24
Funds from Operations-36.20-42.58-37.09-27.57-25.77-19.56
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.883.665.94-7.09-3.786.30
Cash from Operating Activities-37.07-38.91-31.15-34.67-29.55-13.26
Capital Expenditures-0.32-0.34-0.37-0.44-0.23-0.74
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.00-0.000.000.010.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.32-0.34-0.37-0.44-0.22-0.74
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock46.532.26162.760.0610.1314.28
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock46.532.26162.760.0610.1314.28
Proceedsfrom Stock Options46.531.87134.840.0010.1314.28
Issuance or Reduction of Debt, Net0.000.34-20.430.1344.500.00
Change in Long Term Debt0.000.34-20.430.1344.500.00
Issuance of Long Term Debt0.000.62-0.410.1344.500.00
Reduction of Long Term Debt0.00-0.28-20.020.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.35
Other Financing Activities Uses0.000.000.000.000.000.35
Cash from Financing Activities46.532.60142.320.1854.6314.64
Exchange Rate Effect-0.04-0.09-0.04-0.05-0.09-0.20
Net Change in Cash9.11-36.74110.76-34.9724.770.43
Free Cash Flow-37.39-39.25-31.53-35.10-29.78-14.00

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.11%2.7M52.2M1.69M
2026-10-155.77%3.0M52.2M1.82M
2026-09-307.07%3.5M49.0M1.76M
2026-09-156.56%3.2M49.2M1.74M
2026-08-316.07%3.0M49.8M1.59M
2026-08-146.08%3.2M52.6M1.46M
2026-07-317.78%3.2M40.5M1.20M
2026-07-156.69%3.3M48.7M1.28M
2026-06-306.15%3.0M48.7M1.18M
2026-06-157.92%3.1M39.3M981.15K
2026-05-297.12%2.8M39.3M1.18M
2026-05-156.65%2.6M39.3M1.18M
2026-04-306.46%2.5M39.3M1.16M
2026-04-158.50%3.3M39.3M792.23K
2026-03-318.70%3.4M39.3M790.71K
2026-03-139.00%3.5M39.3M856.36K
2026-02-278.45%3.3M39.3M668.64K
2026-02-137.73%3.0M39.3M652.99K
2026-01-306.66%3.0M44.3M703.64K
2026-01-156.93%3.1M44.2M871.36K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.505.408.906.1517.47112.000.000.963-0.0470.001
call4.003.706.805.258.9772.000.000.936-0.0530.002
call5.002.506.704.309.5531100.000.917-0.0510.002
call6.001.956.000.008.6880.000.000.842-0.1020.004
call7.500.502.902.552.8831,4611.000.773-0.0900.005
call9.000.452.101.402.99810.000.000.669-0.1260.006
call10.001.301.701.403.00753418.000.573-0.1030.006
call11.000.801.701.153.57235.0029.000.524-0.1200.006
call12.500.551.050.753.15584513.000.397-0.1030.006
call14.000.004.900.053.1491.000.000.310-0.0940.005
call15.000.150.650.333.2211,9411.000.273-0.0910.005
call16.000.004.900.002.8210.000.000.182-0.0630.004
call17.500.000.300.152.9734620.000.154-0.0600.004
call20.000.000.300.213.4013750.000.140-0.0640.003
call22.500.000.100.102.9868281.000.060-0.0300.002
call25.000.004.800.053.2725981.000.056-0.0310.002
put2.500.000.250.016.9321530.00-0.037-0.0470.001
put4.000.001.200.004.9740.000.00-0.064-0.0520.002
put5.000.000.300.153.8009,8470.00-0.088-0.0490.002
put6.000.004.900.004.9800.000.00-0.158-0.1010.004
put7.500.400.950.643.4851,0573.00-0.228-0.0890.005
put9.000.702.801.304.32414.000.00-0.329-0.1260.006
put10.001.602.152.153.2746712.00-0.427-0.1020.006
put11.000.704.900.005.0670.000.00-0.536-0.0890.006
put12.503.403.904.403.2813020.00-0.602-0.1010.006
put14.003.007.500.007.0600.000.00-0.692-0.0930.005
put15.003.808.506.207.55313.000.00-0.808-0.0580.004
put16.004.609.000.007.8240.000.00-0.818-0.0610.004
put17.506.0010.507.307.3581.000.00-0.846-0.0580.004
put20.008.5013.000.007.6690.000.00-0.859-0.0620.003
put22.5011.0015.500.008.0830.000.00-0.919-0.0380.002
put25.0013.5018.000.008.4860.000.00-0.923-0.0400.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-05SEC
2026-11-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-03SEC
2026-11-023Initial statement of beneficial ownership of securities2026-10-16SEC
2026-10-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-27SEC
2026-10-263Initial statement of beneficial ownership of securities2026-10-13SEC
2026-10-263Initial statement of beneficial ownership of securities2026-10-13SEC
2026-10-233Initial statement of beneficial ownership of securities2026-10-13SEC
2026-10-233Initial statement of beneficial ownership of securities2026-10-13SEC
2026-10-233Initial statement of beneficial ownership of securities2026-10-13SEC
2026-10-233Initial statement of beneficial ownership of securities2026-10-13SEC
2026-10-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-21SEC
2026-10-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-15SEC
2026-10-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-08SEC
2026-10-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-01SEC
2026-10-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-01SEC
2026-10-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-01SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-10-013Initial statement of beneficial ownership of securities2026-09-29SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-22SEC
2026-09-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-21SEC
2026-09-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-21SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-173Initial statement of beneficial ownership of securities2026-09-17SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-10SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-098.63M800
2026-081.04M100
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Venrock Adviser, LLC7.70%
ORBIMED ADVISORS LLC6.54%
ADAGE CAPITAL PARTNERS GP, L.L.C.6.12%
MILLENNIUM MANAGEMENT LLC5.26%
Rosalind Advisors, Inc.3.91%
SPHERA FUNDS MANAGEMENT LTD.3.24%
ACORN CAPITAL ADVISORS, LLC3.08%
Sio Capital Management, LLC2.60%
Nan Fung Group Holdings Ltd1.97%
Boxer Capital Management, LLC1.58%

Funds

Fund% owned
AdvisorShares Psychedelics ETF0.59%

OakChart. HELP. Cached 15 minutes.